Maier-Borst W - Search Results

1

The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.

Stehle G, Sinn H, Wunder A, Schrenk HH, Schütt S, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: maier borst w. Anticancer Drugs. 1997 Aug;8(7):677-85. Anticancer Drugs. 1997. PMID: 9311444

2

Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.

Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W. Hartung G, et al. Among authors: maier borst w. Clin Cancer Res. 1999 Apr;5(4):753-9. Clin Cancer Res. 1999. PMID: 10213209 Clinical Trial.

3

Uptake of indium-111 in the liver of mice following administration of indium-111-DTPA-labeled monoclonal antibodies: influence of labeling parameters, physiologic parameters, and antibody dose.

Schuhmacher J, Klivényi G, Matys R, Kirchgebner H, Hauser H, Maier-Borst W, Matzku S. Schuhmacher J, et al. J Nucl Med. 1990 Jun;31(6):1084-93. J Nucl Med. 1990. PMID: 2348237

4

Enhanced albumin uptake by rat tumors.

Wunder A, Stehle G, Sinn H, Schrenk H, Hoffbiederbeck D, Bader F, Friedrich E, Peschke P, Maierborst W, Heene D. Wunder A, et al. Int J Oncol. 1997 Sep;11(3):497-507. doi: 10.3892/ijo.11.3.497. Int J Oncol. 1997. PMID: 21528238

5

Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia.

Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: maier borst w. Crit Rev Oncol Hematol. 1997 Jul;26(2):77-100. doi: 10.1016/s1040-8428(97)00015-2. Crit Rev Oncol Hematol. 1997. PMID: 9298326 Review. No abstract available.

6

Pharmacokinetic properties of LMW-heparin-tyramine fractions with high or low affinity to antithrombin III in the rat.

Stehle G, Wunder A, Sinn H, Schrenk HH, Harenberg J, Malsch R, Maier-Borst W, Heene DL. Stehle G, et al. Semin Thromb Hemost. 1997;23(1):31-7. doi: 10.1055/s-2007-996067. Semin Thromb Hemost. 1997. PMID: 9156408

7

Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats.

Stehle G, Wunder A, Sinn H, Schrenk HH, Friedrich EA, Dempfle CE, Maier-Borst W, Heene DL. Stehle G, et al. J Surg Res. 1995 Feb;58(2):197-204. doi: 10.1006/jsre.1995.1031. J Surg Res. 1995. PMID: 7861773

8

The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat.

Wunder A, Stehle G, Sinn H, Schrenk HH, Neufeld B, Dempfle CE, Dresel HA, Freidrich E, Harenberg J, Maier-Borst W, et al. Wunder A, et al. Thromb Res. 1995 Apr 15;78(2):139-49. doi: 10.1016/0049-3848(95)00042-9. Thromb Res. 1995. PMID: 7482431

9

Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography.

Schuhmacher J, Klivényi G, Matys R, Stadler M, Regiert T, Hauser H, Doll J, Maier-Borst W, Zöller M. Schuhmacher J, et al. Cancer Res. 1995 Jan 1;55(1):115-23. Cancer Res. 1995. PMID: 7805020

10

Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.

Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H. Wunder A, et al. Among authors: maier borst w. Int J Cancer. 1998 Jun 10;76(6):884-90. doi: 10.1002/(sici)1097-0215(19980610)76:6<884::aid-ijc19>3.0.co;2-2. Int J Cancer. 1998. PMID: 9626357 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results